These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

185 related items for PubMed ID: 23970394

  • 1. When EMA and FDA decisions conflict: differences in patients or in regulation?
    Wolfe SM.
    BMJ; 2013 Aug 21; 347():f5140. PubMed ID: 23970394
    [No Abstract] [Full Text] [Related]

  • 2.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 3. FDA embraces risk-management approach.
    Fox JL.
    Nat Biotechnol; 2003 Oct 21; 21(10):1120-1. PubMed ID: 14520383
    [No Abstract] [Full Text] [Related]

  • 4.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 5.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 6. EMEA approves OGS drug rejected by FDA.
    Mitchell P.
    Nat Biotechnol; 2002 Sep 21; 20(9):858-9. PubMed ID: 12205490
    [No Abstract] [Full Text] [Related]

  • 7.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 8. The FDA's accelerated approval process: does the pharmaceutical industry have adequate incentives for self-regulation?
    Orlando VI.
    Am J Law Med; 1999 Sep 21; 25(4):543-68. PubMed ID: 10629734
    [No Abstract] [Full Text] [Related]

  • 9. Evaluation of oncology drugs at the European Medicines Agency and US Food and Drug Administration: when differences have an impact on clinical practice.
    Trotta F, Leufkens HG, Schellens JH, Laing R, Tafuri G.
    J Clin Oncol; 2011 Jun 01; 29(16):2266-72. PubMed ID: 21537038
    [Abstract] [Full Text] [Related]

  • 10.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 11.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 12.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 13.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 14. What ails the FDA?
    Jenny-Avital ER.
    N Engl J Med; 2005 Jun 16; 352(24):2554-5. PubMed ID: 15962407
    [No Abstract] [Full Text] [Related]

  • 15. FDA performance goals for approving drugs and biologics.
    Miller JD.
    JAMA; 2009 Jul 08; 302(2):189-91. PubMed ID: 19584348
    [No Abstract] [Full Text] [Related]

  • 16.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 17.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 18. Drug safety on trial.
    Nature; 2005 Mar 31; 434(7033):545. PubMed ID: 15800579
    [No Abstract] [Full Text] [Related]

  • 19.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 20. Initial responses to recommendations of the Blue Ribbon Committee on Generic Medicines.
    Heller WM.
    Am J Hosp Pharm; 1993 Feb 31; 50(2):318-22. PubMed ID: 8480792
    [No Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 10.